US consumers are shielded from the cost of healthcare

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed.

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed. There is, however, one recommendation that Dr. Saving alluded to, but did not emphasize, when he stated that "beneficiaries are shielded from the fiscal realities of the medical care they consume."

This situation is further exacerbated by the care delivered, especially end-of-life-care, at the patient's directive. Thus, often patients and their families want everything done because that is the only way the patient can stay in the hospital and avoid home care and costs. Often these patient directives also economically benefit the caregivers.

In the current healthcare system, there are lots of winners. The only losers are the next generation of Americans, who will be left with the tab.

Unless we use incentives and disincentives in healthcare by denying payment and/or enforcing Dr. Saving's advice that "the first dollars spent on healthcare are the responsibility of the consumer," the US healthcare delivery system is unlikely to see much improvement.

Gilbert A. Lawrence, MD, DMRT, FRCRRadiation Oncology, Faxton Hospital Cancer CenterUtica, New York

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content